Results 231 to 240 of about 2,878,616 (306)

Psychometric properties of the Chronic Rhinosinusitis Patient-Reported Outcome (CRS-PRO) questionnaire in a Spanish population. [PDF]

J Patient Rep Outcomes
Montilla-Ibáñez MA, García-Fernández JM, Díaz-Fernández Á, López-Ruiz MDC, Fábrega-Cuadros R, Lomas-Vega R.   +5 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Development and Validation of a Patient-Reported Outcome Measure for Female Genital Labia Procedures: The LABIA-Q. [PDF]

Aesthet Surg J Open Forum
Kaur MN, Cornacchi SD, Rae C, Furnas HJ, Sorice-Virk S, Ziolkowski N, Pusic A, Klassen AF.   +7 more
europepmc   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Systematic review of patient-reported outcome measures for opioid use disorder recovery. [PDF]

Addiction
Pytell JD, Pales D, Simon C, Beaudoin J, Osman AMY, Svoboda E, Christine PJ, Matlock D, Schwartz R, Binswanger IA.   +9 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Assessing the assessment: a scoping review of the mode of patient-reported outcome assessment in solid cancer clinical trials. [PDF]

Qual Life Res
Hubel N, Krepper D, van der Weijst L, Machingura A, Seidl C, Vorbach SM, Veil M, Giesinger JM, Sztankay M, Kern S, Fitzsimmons D, Kuliś D, Pe M, Holzner B, Lehmann J, EORTC Quality of Life Group.   +15 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Patient-reported outcome measures in patients with systemic lupus erythematosus with or without concurrent fibromyalgia. [PDF]

Lupus
Gold HT, Li Y, Anthopolos R, Buyon JP, Masson M, Cohen B, Gutowski E, Saxena A, Belmont HM, Tseng CE, Corbitt K, Izmirly PM.   +11 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source